Drug intelligence / Profile preview

CBT-011

Development stage: Preclinical
Lead developer: Cloudbreak Pharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

CBT-011 is an antibody-drug-synergism (ADS) conjugate developed for the treatment of diabetic macular edema (DME), a retinal disease characterized by fluid accumulation in the macula due to hyperpermeability of retinal blood vessels. The drug utilizes Cloudbreak Pharma's proprietary ADS technology platform, which enables multi-targeting mechanisms and aims to generate synergistic effects between different therapeutic modalities, potentially offering more effective treatment than single-agent therapies. As of the latest information, CBT-011 is in preclinical development[1][2].

Beyond the preview

Go deeper on CBT-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT-011.

Explore the full profile